WeVote
Log In

Bill

Bill

HB 877

Active Pharmaceutical Ingredients

2026 Regular Session Introduced by Traci Koster

HB 877 establishes Florida regulations for active pharmaceutical ingredients to govern their manufacturing, distribution, and quality standards affecting drug safety and accessibility.

1st Reading (Original Filed Version)
#regulationofprofessionsandoccupations
0
WeVote Research Nonpartisan
Bill Summary · HB 877

Legislative bill overview

HB 877 addresses the regulation and oversight of active pharmaceutical ingredients (APIs) in Florida, likely establishing standards for their manufacturing, distribution, or quality control. The bill is currently in early stages of the legislative process, having just been filed and referred to multiple health-related committees for review.

Why is this important

APIs are the chemically active components in medications that produce therapeutic effects. Regulating their quality and sourcing directly impacts drug safety, efficacy, and cost for Florida residents. This bill could affect pharmaceutical supply chains, prices, and manufacturing standards within the state.

Potential points of contention

  • Drug pricing impact: Stricter API regulations may increase manufacturing costs, potentially raising medication prices for consumers
  • Federal vs. state authority: APIs are primarily regulated by the FDA federally; state-level regulation could create compliance conflicts or duplicative oversight
  • Manufacturing feasibility: Enhanced requirements could discourage pharmaceutical manufacturing in Florida or burden in-state facilities with additional compliance costs

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.